Concord Medical Expands Strategic Collaboration with Mayo Clinic to Build a Comprehensive Health Management Ecosystem
Concord Medical, a leading oncology-focused healthcare group in China listed on the Hong Kong Stock Exchange (02453.HK), announced today that it has signed a new round of strategic cooperation agreement this month with Mayo Clinic.
Building on years of solid collaboration and mutual trust, this agreement marks a new phase in the partnership, expanding its scope from the internationalization and standardization of oncology care to a full lifecycle health service model, encompassing disease prevention, screening, rehabilitation, and long-term health management.
As a pioneer in international collaboration in China’s oncology sector, Concord Medical has long been committed to introducing world-class medical resources, clinical expertise, and management standards into China. Early on, the Group established a deep partnership with the globally recognized cancer center, MD Anderson Cancer Center, working closely across hospital development and operations, discipline building, and quality management. This collaboration has enabled Concord Medical to systematically build a leading precision oncology care system in China, while gradually shaping an international cooperation strategy centered on “whole-person, full-cycle care,” promoting both precision cancer treatment and proactive health management throughout the patient journey.
Building on this foundation, Concord Medical also initiated cooperation several years ago with another global benchmark institution, Mayo Clinic. The partnership spans joint training of proton therapy professionals, cross-border second opinions and referrals for complex cases, hospital leadership development, and the establishment of internationally aligned quality management systems. These sustained efforts have laid a strong foundation of mutual trust and practical collaboration experience between the two parties.
This collaboration serves as a key vehicle for deepening the partnership between Concord Medical and Mayo Clinic, through which Mayo Clinic’s advanced service systems, operational standards, and clinical expertise will be further integrated into Concord Medical’s business framework. Mayo Clinic will support this initiative through a comprehensive, end-to-end approach, including remote care planning, immersive on-site training at its U.S. campuses, virtual implementation guidance, on-site evaluations, and ongoing post-implementation assessment and support.
This process will facilitate the full adoption of a mature health management model, spanning key areas such as service design, clinical pathways, patient experience, and operational efficiency. Leveraging the strong foundation of prior collaboration, Concord Medical will continue to enhance its integrated healthcare service capabilities, refining a full-cycle care continuum that connects prevention and screening, precision diagnosis and treatment, and post-treatment rehabilitation and management.
This expanded partnership reflects Concord Medical’s dual strategic focus on deepening specialty care and broadening comprehensive health services, with the goal of delivering a seamless, end-to-end healthcare solution that supports patients from disease treatment through long-term health management.
After years of sustained development, the results of **Concord Medical’s “bringing in” strategy have become fully evident. Its affiliated hospitals have achieved international alignment in patient services, clinical quality, and talent development. Leveraging extensive clinical data, the Group has independently developed a large language model for proton therapy, enabling the deep integration of AI technologies with precision radiotherapy and further strengthening its technological capabilities.
More importantly, the capabilities built through this “bringing in” approach are rapidly translating into a competitive edge for “going global.” Since its launch in late 2024, the proton therapy center at Guangzhou Concord Cancer Center has served patients from all 31 provinces, municipalities, and autonomous regions across China, while also extending services to more than 20 countries and regions, with a steadily growing number of international patients—primarily those with complex tumors requiring precision radiotherapy.
On the international front, Concord Medical has established partnerships in countries including Indonesia, Pakistan, Bangladesh, and Uzbekistan. In 2026, it signed an agreement with National Hospital Surabaya to jointly develop an oncology center, exporting its management systems, clinical standards, and AI technologies. Recently, medical institutions from Russia and Kazakhstan have also visited for collaboration discussions, contributing to the gradual formation of a cross-border healthcare service network spanning Southeast Asia, South Asia, Central Asia, and Russia.
From introducing international standards, to implementing flagship projects, and now to exporting capabilities and serving patients worldwide, Concord Medical is forging a distinctive path of international development. This latest deepened collaboration with Mayo Clinic further communicates a clear long-term strategic logic to the market and its shareholders: to build on international partnerships, leverage core technologies and operational capabilities, and utilize a nationwide healthcare network as the platform—ultimately forming a closed-loop model of “introducing international standards → local capability development → global expansion.”
For investors, Concord Medical’s value extends beyond the profitability of individual projects. It lies in the Group’s ongoing effort to build a replicable, scalable, and continuously upgradable high-end healthcare service system. As collaboration continues to deepen, the number of international patients grows steadily, and the global healthcare network expands, Concord Medical is entering a new phase of capability realization and value creation. While contributing to the advancement of high-quality healthcare services in China, the Group is also well-positioned to deliver sustainable long-term value for its shareholders.